sodium phosphate 16% / 6% rectal solution
lab. chimico farmaceutico a sella s.r.l via vicenza 67, schio, italy - sodium phosphate, dibasic dodecahydrate, monobasic dihydrate - rectal solution - sodium phosphate dibasic dodecahydrate 8 % (w/v) sodium phosphate monobasic dihydrate 18.1 % (w/v) - drugs for constipation
normacol enema adults
norgine pharma 87 avenue de la grande armée, 75782 paris cedex 16, france - sodium dihydrogen, phosphate dihydrate, sodium phosphate, dibasic dodecahydrate - rectal solution - sodium dihydrogen phosphate dihydrate 23.66 g sodium phosphate dibasic dodecahydrate 10.4 g - drugs for constipation
phospho-soda 24.4g/10.8g oral solution
casen-recordati s.l. - sodium phosphate dibasic dodecahydrate; sodium phosphate dibasic dihydrate - oral solution - 24.4/10.8 gram(s) - osmotically acting laxatives
fleet phospho-soda 24.4g/10.8g oral solution 24.4/10.8 grams oral solution
laboratorios casen-fleet s.l.u. - sodium phosphate dibasic dodecahydrate sodium phosphate dibasic dihydrate - oral solution - 24.4/10.8 grams
sodium valproate wockhardt sodium valproate 1000 mg/10 ml solution for injection ampoule
wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.
sodium valproate wockhardt sodium valproate 400 mg/4 ml solution for injection ampoule
wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.
dibasic sodium phosphate, monobasic potassium phosphate and monobasic sodium phosphate- dibasic sodium phosphate, monobasic pota
american health packaging - sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (phosphate ion - unii:nk08v8k8hr), potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr) - sodium phosphate, dibasic, anhydrous 852 mg - phospha 250 tm neutral increases urinary phosphate and pyrophosphate. as a phosphorus supplement, each tablet supplies 25% of the u.s. recommended daily allowance (u.s. rda) of phosphorus for adults and children over 4 years of age. this product is contraindicated in patients with infected phosphate stones, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia.
dibasic sodium phosphate, monobasic potassium phosphate and monobasic sodium phosphate tablet
rising pharmaceuticals, inc. - sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (phosphate ion - unii:nk08v8k8hr), potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr) - sodium phosphate, dibasic, anhydrous 852 mg - phospha 250tm neutral increases urinary phosphate and pyrophosphate. as a phosphorus supplement, each tablet supplies 25% of the u.s. recommended daily allowance (u.s. rda) of phosphorus for adults and children over 4 years of age. this product is contraindicated in patients with infected phosphate stones, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia.
dibasic sodium phosphate, monobasic potassium phosphate and monobasic sodium phosphate tablet
carilion materials management - sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (phosphate ion - unii:nk08v8k8hr), potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr) - sodium phosphate, dibasic, anhydrous 852 mg - phospha 250 neutral increases urinary phosphate and pyrophosphate. as a phosphorus supplement, each tablet supplies 25% of the u.s. recommended daily allowance (u.s. rda) of phosphorus for adults and children over 4 years of age. tm this product is contraindicated in patients with infected phosphate stones, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia. . see dosage and administration
sodium phosphates- sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous injection, solution
hospira, inc. - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37), sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37) - sodium phosphate, monobasic, monohydrate 276 mg in 1 ml - sodium phosphates injection, usp, 3 mm p/ml is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. the concomitant amount of sodium (na+ 4 meq/ml) must be calculated into total electrolyte dose of such prepared solutions. sodium phosphate is contraindicated in diseases where high phosphorus or low calcium levels may be encountered, and in patients with hypernatremia.